Ossama Elsaid, MD
Interventional Cardiology · Edison, NJNPI 1467799353
Payments from drug & device makers
What this record shows
This record is dominated by grants: $28,500 of the $34,008 with a category attached, or 83.8%. 18 manufacturers reported payments, led by Medtronic at 47.6% of the total. 2025 is the largest year on record at $32,605, more than ten times the $76 reported in 2019.
Across 86 payments — averaging $395.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Abbott$14K
- Edwards Lifesciences$3K
- Boston Scientific$561
- Abiomed$409
- Penumbra, Inc.$175
- plus $568 from 12 others
What the payments were for
- Grants$28,50084%
- Travel & lodging$2,2287%
- Food & beverage$3,2199%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $16,173 |
| Abbott | 7 | $13,607 |
| Edwards Lifesciences | 23 | $2,516 |
| Boston Scientific | 11 | $561 |
| Abiomed | 14 | $409 |
| Penumbra, Inc. | 3 | $175 |
| Chiesi USA, Inc. | 1 | $132 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Inari Medical, Inc. | 1 | $71 |
| Pfizer | 2 | $44 |
| Biosense Webster, Inc. | 1 | $36 |
| Shockwave Medical, Inc | 2 | $35 |
| AstraZeneca | 2 | $28 |
| Philips North America LLC | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Boehringer Ingelheim | 1 | $17 |
| Novartis | 1 | $17 |
| Vital Connect, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$13,500
- SAPIEN 3 Ultra RESILIA$478
- COREVALVE EVOLUT R$471
- ONYX FRONTIER$149
- KENGREAL$132
- Diamondback Coronary$124
How this compares
$34,008 in reported general payments places this provider in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 14 | $135 |
| Rosuvastatin Calcium | 17 | $122 |
| Carvedilol | 11 | $85 |
| Metoprolol Tartrate | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Edison
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
- Dimitrios KarmpaliotisMorristown$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.